Abstract:Introduction: OMICS is the term used to designate new biological sciences investigating a large group of molecules in biological samples. For instance, genomics and transcriptomics study changes in genome and transcription expression respectively. Numerous others OMICS are emerging (e.g. epigen-, prote-, metabol-, lipid-, glucid-OMICS). Support from bioinformatics and biostatistics, together with new molecular biology technologies for screening these large molecular groups (i.e. high-throughput biological arrays), has led to the development of these scientific fields. They help to draw relevant molecular identity cards of tumors. State of the art: Glial tumors form a heterogeneous morphological and clinical tumor group including astrocytomas (from grade I to IV), oligodendrogliomas and oligoastrocytomas (grades II and III). OMICS has enabled a better understanding of clinical and biological behavior of these tumors identifying new molecular abnormalities and relevant biomarkers (i.e. diagnostic, prognostic, predictive of response to treatments and predisposing to gliomas). BRAF abnormalities are diagnostic markers in pilocytic astrocytomas and pleomorphic xanthoastrocytomas (duplication with rearrangement and V600E mutation, respectively). Translocation (1;19)(q10;p10) is associated with oligodendroglial phenotype and better prognosis in gliomas. MGMT promoter methylation is predictive of response to chemotherapy in grade IV astrocytomas (GBM). In GBM, high-throughput studies have discovered: genetic and genomic disruption of tyrosine kinase receptors, TP53 and RB signaling pathways in the vast majority of cases; several transcriptomic (e.g. neural, proneural, classic and mesenchymal), epigenomic (e.g. CpG Island Methylator phenotype versus non methylator phenotype) and proteomic (e.g. EGFR, PDGFR and NF1) patterns with biological and/or clinical impacts. Finally, OMICS have identified recurrent IDH1/IDH2 mutations with prognostic significance in glial tumors and five single nucleotide polymorphisms associated with susceptibility to gliomas (e.g. TERT, CCDC26, PHLDB1, RTEL1 and CDKN2A/CDKN2B). These latter data combined with already known inherited cancer syndromes (i.e. Turcot type 1, Cowden, melanoma-astrocytoma, Li-Fraumeni, tuberous sclerosis complex, type I and II neurofibromatosis) improve our knowledge of genetic predisposition to gliomas. Perspectives: Data generated by OMICS are huge, multidimensional and promising. Bioinformatics and biostatistics will allow their integration (integromics) toward a precise dissection of their clinical of biological significance in neuro-oncology. Conclusions: OMICS have a growing impact in neuro-oncology improving basic research in brain tumors and clinical management of patients through the discovery of biomarkers.

Utility of combining OLIG2 and SOX10 IHC expression in CNS tumours: promising biomarkers for subtyping paediatric‐ and adult‐type gliomas

Quantitative Proteomic Analysis of Oligodendrogliomas with and Without 1p/19q Deletion

Diagnostic Utility of Immunohistochemical Detection of MEOX2, SOX11, INSM1 and EGFR in Gliomas

Immunological profiles of human oligodendrogliomas define two distinct molecular subtypes

Oligodendrocyte Transcription Factor 2 as a Potential Prognostic Biomarker of Glioblastoma: Kaplan-Meier Analysis and the Development of a Binary Predictive Model Based on Visually Accessible Rembrandt Image and Magnetic Resonance Imaging Radiomic Features

Path-36. Do Gene Expression Profiles Better Predict Oligodendroglioma Survival?

Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2

Biom-30. Novel Histologic And Molecular Biomarkers For Oligodendroglioma

Prognostic significance of oligodendrocyte transcription factor 2 expression in glioma patients: A systematic review and meta-analysis

SOX9+ malignant cells define a poor prognosis subtype of Glioma with tumor-associated macrophage recruitment

Glioma SOX2 Expression Decreased after Adjuvant Therapy.

PO-336 Identification of SOX2 and SFRP2 As Opposing Regulators of Glioblastoma Heterogeneous Subtypes

Exploring the role of SOX 2 and OCT 4 in the pathogenesis of gliomatosis peritonei: the clinicopathological profile of eleven cases

Increased NG2 and SOX2 Expression is Associated with High-Grade Choroid Plexus Tumors.

Examination of PHOX2B in adult neuroendocrine neoplasms reveals relatively frequent expression in phaeochromocytomas and paragangliomas

Prognostic value of stem cell markers in glioblastoma

SOX11, SOX10 and MITF Gene Interaction: A Possible Diagnostic Tool in Malignant Melanoma

Expression-based Intrinsic Glioma Subtypes Are Prognostic in Low-Grade Gliomas of the EORTC22033-26033 Clinical Trial.

The SOX2 Response Program in Glioblastoma Multiforme: an Integrated ChIP-seq, Expression Microarray, and Microrna Analysis

[OMICS and biomarkers of glial tumors]

A comprehensive analysis of SOX17 expression by immunohistochemistry in human epithelial tumors, with an emphasis on gynecologic tumors